CHRONIC ILLNESS- MANAGED ANTIAGING ANTI AGING ANTI-AGING CLINIC SOUTH AFRICA

 

update 24 May 2011

In Claremont  and Fish Hoek , Cape Town

A Specialist Internist Clinic offers consultations by appointment especially for managing (and ideally preventing)  the major chronic degenerative diseases of aging  and  maintaining physical, mental (and why not sexual?) vigour to a ripe and healthy old age.

The clinic (a specialist physician and a nutritionalist)  offers all-system evaluation and if available, natural  (as well as essential prescription orthrodox) prevention/treatment including metabolic – weight-endocrine-diabetes; heart-lung -kidney; hypertension; neurological-pain; joint & muscle; abdominal, immune system ie infection and cancer and auto-immune  support;  genito-urinary & sexual problems;

and appropriate screening – ECG, non-xray ( no-touch thermography- eg thermomammogram;   SureTouch tactile) mammograms, non-xray (ie  ultrasound) BMD ie  bone fracture risk measurement, body composition, and appropriate hormone profiling/replacement.

Phone during office hours for appointment: for Claremont or Fish Hoek ph 021-6717415  or 6831465 (or 083-6299160) – at Grove Medical Bldg 1st floor no 15 (opp ABSA Bank Parkade c/o Grove Ave Pearce Rd)  , or neil.burman@gmail.com ; or at Fish Hoek  enquire of Coral : 782-2024 or kilbaigie@mweb.co.za   or consultation by telephone/Skype or email .

HOURS: by appt: Claremont:  9am-5pm weekdays, 9am-1pm Saturdays.

                                  Fish Hoek: “Hove To” Specialist Rooms c/o 3rd Ave/Kommetjie Rd – on the 2nd Tuesday after the 2nd Friday each month – 9am -1pm if there are enough bookings to justify a clinic there.

Urgent cases will be dealt with if practical.    But acute emergencies and trauma, bleeding cases  cannot be dealt- these must go to the Emergency Unit at Claremont Clinic 500m away. .

Billing according to means ie specialist professional rates:  eg as a preferred provider for Discovery Health- rate currently R626.70 per  consultation procedure  019; for needy patients, what the medical scheme pays eg R360. Detailed medical report and advice protocol provided at R300. Even Hospital Plans have to pay for outpatient consultation for scores of PMBs ie Prescribed Medical benefit conditions like Menopause.

 Needy patients desiring brief consultation can be seen by arrangement at GP rate.    Bone density scan  (covered by some medical schemes)  procedure 3612  - R250.  Non-xray mammograms are not yet covered by medical schemes codes: R300 for SureTouch, R600 for thermomammogram.

UPDATES: HEALTHY LIVING

This  blog is irregularly updated   with the latest detailed pharmacological information on the ingredients of anti-aging preparations, the powder blend compositions, and mail-order/wholesale prices.

These are all detailed  on the page Product Details and Pricelists. but of course all the ingredients, as food supplements, can be ordered individually to US  or UK  or Japanese pharmacopoea standard anywhere from any reliable importer or manufacturer.

The prices listed are not updated weekly, they are a guide; and  dependent from day to day on imported costs which are mostly rising constantly .

For information email sales@healthspanlife.com (or contact 027836299160).

The public, as well as interested distributors/retailers, are invited to contact Healthspan Life!.

INDEX OF RECENT MAIN TOPICS

MANAGED ANTIAGING CLINIC CONSULTATIONS

PRODUCT DETAILS AND PRICE LISTS;     SUPPLEMENTS AGAINST DISEASE, AGING

UPDATES

SWINE FLU UPDATE; Tamiflu protection?- evidence please? A windfall for USA?

NEGLECTED ESSENTIALS: CoQ10.. VITAMIN D... B12 ; STEVIA; FISH OIL; FAT-SOLUBLE SUPPLEMENTS;

OPIOIDS  NOT NSAIDS IF PANADO  DOESNT  SUFFICE ..ACETAMINOPHEN/ PARACETAMOL RISKS .. WHY USE OTHER THAN PARACETAMOL FOR MILD PAIN?

VESTED INTERESTS IN RISING COSTS

THE MOST IMPORTANT DRUG THERAPY OF HYPERTENSION..  DRUG LISTS .. WHY IGNORE RESERPINE?..

DIABETES, METFORMIN: THE FIRST DIABETES PREVENTION PROGRAM: CHINA… PREVENTION OF OBESITY, DIABETES; PREGNANCY & METFORMIN .. METFORMIN FIRST INSULIN TRIPLES DEATHS ; THE  30 year  UKPDSPREDIABETES TIME BOMB;

DEMENTIA ETANERCEPT;FUTILE MODERN DRUGS;

DANGER, BIAS   OF RANDOMIZED CONTROLLED TRIALS;

THE WOMENS’ HEALTH INITIATIVE WHI:  MISPLANNED, MISREPORTED &  MANIPULATED;

HOMEOPATHY..

SOUTHERN  AFRICAN APOCALYPSE

ESTROGEN+INSULIN vs TESTOSTERONE+METFORMIN ..APPROPRIATE HRT SEX HORMONE REPLACEMENTANDROGENS  GIVE HEART STRENGTH AND HEALTH. NON-ORAL HRTDVT AFTER ORAL HT;

SCAMS & SNARES: STATINS; BISPHOSPHONATES; SCREENING MAMMOGRAPHY; BLACK COHOSH; RIMONABANT; GLITAZONES; FORTEOTIBOLONE;

ARTHRITIS: MULTIPLE EFFECTIVE NATURAL REMEDIES;

CANCER: PROGESTINS; HRT; PROSTATE ; HYPOCHOLESTEROLEMIA ;

SEX: persistent female genital arousal syndrome.

SPECIALIST CHRONIC DISEASES CLINIC OF EXCELLENCE

   a Specialist Internist Physician [MB,ChB(UCT 1966), MRCP (UK 1974),   (fellow of the     Kronos Longevity Research Institute, Phoenix, Arizona 2004)  has opened a   CHRONIC DISEASE CLINIC    

 at Grove Medical Bldg, Grove Ave Claremont Cape Town  bewteen

ABSA Bank Parkade &  Warwick Sq opp. Cavendish Sq (also at Fish Hoek).

MISSION: To address the underlying causes of disease not just the symptoms,  to delay by decades all-cause disability and deaths.    Integrating natural and modern medicine.

managing and if possible delaying all common concurrent diseases of aging

including especially fatigue, frailty, diabetes;

 hypertension, cardiovascular, neurological, respiratory,

 abdominal, pain, headache, neurological -memory, renal, genitourinary,

endocrine , musculoskeletal, sexual and  immune diseases . 

Appropriate physiological Menopause and Aging Male HRT .

No-xray osteoporosis/BMD measurement by quantitative ultrasound.

Distance consulting.

phone/fax  +27216717415  for appointment, or respond below. .

2011 in review

The WordPress.com stats helper monkeys prepared a 2011 annual report for this blog.

its informative to see what the most people seek out.

 

Here’s an excerpt:

The concert hall at the Syndey Opera House holds 2,700 people. This blog was viewed about 19,000 times in 2011. If it were a concert at Sydney Opera House, it would take about 7 sold-out performances for that many people to see it.

Click here to see the complete report.

THE GROWING RISKS OF CHEMO-FOG; THE ETHICAL DILEMMA OF INFORMED CONSENT. WHAT SHOULD BE OBLIGATORY SCREENING?

neil.burman@gmail.com.      for debate.

ETHICAL CONSIDERATIONS: given the increasing evidence of cognitive and mood effects of cancer and fear on patients with extracranial cancer, let alone after chemo-and radio-therapy, it becomes a major ethical issue as to whether the patient alone should be the decision-maker in the fearmongering-driven decision about whether  to have xray-screening mammography  or prostate  or colon cancer screening in the absence of symptoms and familial high risk.

Similarly, given the epidemic nature of HIV-AIDs and  overweight-prediabetes-Hypertension in Africa, and the giant public cost of illness and deaths  from these diseases, should screening and treatment  for these be voluntary or compulsory?

Equally, are patients diagnosed with cancer, hypertension or HIV-AIDs  competent to make decisions alone for themselves about cancer or other  therapy? Can the patient alone decide about active interventions, versus withdrawal from all therapy – giving up and accepting death – when there are so many options that may help and even cure despite advanced cancer, AIDs and diabetes-hypertension. Surely the patient’s most responsible relative needs to be involved.

  We frequently see such patients plunge into therapy, or withdraw from therapy to die. Current cancer reviews from America, Italy and Portugal  explore this need for truly informed consent. and adequate support for cancer, AIDs and hypertension. 

The need is as great in  AIDs- HIV infection- in our local state AIDs  clinics,   patients have to bring along a buddy, someone – partner, family or friend – from their neighbourhood- who can be relied upon to support the patient through thick and thin, ensure compliance with both complicated drug therapy and all aspects of nutrition and function in consultation with the medical and social backup team.

BACKGROUND:

The analogy of Cancer  with AIDs and overweight-prediabetes-hypertension  is strong. With HIV-AIDs there is oftem  inital  anxiety and depression in anticipation of the screening test, especially in someone who has symptoms; and then if the test is positive. more guilt, anger, fear and despair needing support till the patient adjusts to living with HIV and the necessary prevention and precautions;  until the cycle repeats itself when deterioration necessitates active therapy for active AIDs ARVs (antiretroviral therapy) and if necessary antituberculous therapy. . Both AIDs and ARVs can seriously affect both mood, cognition and thus behaviour. The latest Pubmed  reviews are  from Spain and USA.

 In survivors of brain cancer as well as cancer outside the nervous system, the effects of radiotherapy on the brain’s longterm mental, sensory, cognitive  and motor  function and hormone output, are well known, even in the absence of nervous system malignancies or direct nervous system therapeutic irradiation. The same applies to the deadly longterm consequences of untreated overweeight-prediabetes-hypertension and HIV-AIDs.

Cramond 1968 is the earliest reference found on Pubmed search  (for cognitive impairment and cancer),  an omnibus pair of articles that reviewed all of organic psychosis – cognitive, mood and behaviour effects on the brain of organic disease;  but in the second article   he  quoted only a case of intracranial cancer.  He did not refer to brain effects of extracranial cancer or chemo-radiotherapy.

The first report of brain impairment after combined radio-chemotherapy appears on Pubmed in 1978.  

“ Affective and cognitive effects of chemotherapy in cancer patients”   was  first linked in 1980  by  Silberfarb PM, Philibert D, and Levine PM         

 and Chemo brain in  a 2005 review  of  cognitive impairment in patients before any treatment. 

 By 2007 chemo fog was no longer regarded as an illusion in a major New York Times review

There are increasing numbers of long-lived survivors of cancer treatment -especially in middle-aged ie prime-time women after breast cancer. .

Now teams from Amsterdam and Oxford universities 2011,  and Harvard 2010,   show cognitive impairment is common long term in survivors treated even only with cancer chemotherapy for non- nervous system cancers. . This is associated with predictable white and grey matter damage from cytotoxic drugs- such poisons naturally damage healthy as well as killer cells.

 This was and is  the deadly fallacy of the profiteering screening xray mammography industry marketeering that “xray mammography saves lives” highlighted previously in this column, that lowdose irradiation and chemotherapy would not damage healthy tissues. .

Obviously this  cognitive impairment long term with cancer, and iatrogenic after chemo/radiotherapy,  must also be weighed up by the patient who faces multiple choices of therapies for cancer – especially as conventional allopathic cancer therapy does not cure even 10% of all cancers.

Most patients who die old – with or without a history of cancer- have some usually undiagnosed ie dormant cancer somewhere in their body.

This applies also to those considering having invasive screening tests for clinically asymptomatic cancers of eg the breast and prostate, for which the wished-for longterm benefits of preclinical diagnosis and treatment have been disproven, indeed discredited by the risks.. As a result, even the value of colon screening for all is being increasingly questioned in the asymptomatic without family history of colon disease.

This doubt about screening obviously falls away in patients who have strong risk (from previous cancer or family history) of the Big Five sexhormone-linked cancers – breast, prostate, colon, endometrium and ovary.

 Obviously accumulating life stresses, familial anxiety-depression and dementia,  aging-related vascular disease, smoking, alcohol, virus infection, multiple hormone and other imbalances (dietary and minerals; vitamin- and other biologicals) will compound the problem of cancer-therapy-associated mood, cognitive and behavioural  impairment. These need anticipation ie simple holistic prevention with safe natural supplements from as young as possible, to prevent both cancer and the other common comorbid degenerative diseases of aging.

The authoritative Life Extension Foundation lists many useful and often evidence-based brain-protective supplements.

www.cancer-prevention.net  is a comprehensive review of different strategies, although it strangely discredits itself because it is incomprehensibly undated, anonymous and unreferenced. .

 But each putative individual supplement can be simply referenced for it’s evdence base  on Google and Pubmed.

CONCLUSION: Like untreated asymptomatic hypertension, diabetes,  menopause and AIDs, cancer screening let alone cancer itself is often associated with  organic brain problems-  depression, cognitive and perhaps behavioural.  These require  evaluation and consideration at all time, especially in regards to invasive screening and management- or avoidance of these. Is eager consent to invasive screening or invasive therapy- or refusal thereof - truly informed ethical consent, understanding of benefits and risks?

 The similarity  between hypertension, HIV-AIDs and cancer is that both avoidance of risk factors, lifestyle and supplements can make a major difference.

The difference is that many cancers can be left well alone, the immune system optimized by optimal diet-lifestyle and supplements, with permanent remission or progression often unaffected by conventional allopathic cancer therapy. In asymptomatic eg lung, prostate and breast cancer, and eg asymptomatic chronic leukemia,  screening of those not  symptomatic, not at high risk is thus fultile. Treatment can wait till cancer if ever presents clinically, while all practice sensible prevention.

 In HIV carriers and asymptomatic overweight-prediabetes-hypertension in  Africa at least,  only a tiny proporttion will not progress to terminal AIDs or malignant diabetes-hypertension, so regular monitoring is necessary to decide when to start ARVs and metformin plus antihypertensives to prolong life and health for decades. It can be strongly arguesd that compulsory periodic HIV and waistgirth and bloodpressure screening are both lifesaving and in the public interest since early diagnosis and mandatory intervention can be life-and health-saving.

Helen Zille, the Leader of the Opposition here, has the last word this morning, on the paradigm shift in thinking needed  in ‘Tackling the new AIDs denialism’.

Is recklessly spreading AIDs by unprotected sex- as African male culture apparently still promotes despite the outrage the promiscuous  then deputy-president Jacob Zuma himself provoked a decade ago in his rape trial- any different from reckless promotion of harmful screening xray mammography, or the legislative ignoral of the need for regular mandatory screening for hypertension and HIV?

NEGLIGENT PROMOTION OF SCREENING XRAY MAMMOGRAPHY AS SAVING LIVES.

neil.burman@gmail.com

Two weeks ago, in response to mounting international concern for the welfare of older women, the UK government announced that it is setting up an independent review of the risks and benefits of xray mammography screening. 

 It has been publicised since the 1970s that low-dose mammographic irradiation may increase risk of breast cancer 4 (to 6) fold, and more so in women with a genetic risk. (Heyes ea 2006 Dept Medical Physics Birmingham Hospital UK; publicised studies -including from survivors of atomic bomb exposure).

A new French study published this month confirms in human breast cancer cells that a significant dose-effect of lowdose irradiation was observed, “with an exacerbation in high-risk compared to low-risk patients (p = 0.01). The dose repetition (2 + 2 mGy) provided more induced and more unrepaired DSB than 2 mGy and 4 mGy, and was exacerbated in HR (p = 0.006). ”

 Just three weeks after the last review in this column of the mounting evidence against xray breast screening, at least 4 more major studies (three from USA) have been published the past month refuting the marketing spiel that “Xray screening Mammography Saves Lives” :

1. A trenchant debunking appeared in the New York Times a fortnight ago based on the latest USA Dartmouth University study of USA 20 year national Breast cancer statistics published in a leadng medical journal that day It concluded: “Most (87% to 97% of) women found to have breast cancer by xray screening are not helped by the test. Only some 4% to 8% of women with breast cancer so detected are helped by such screening. Most are instead either diagnosed early (with no effect on their mortality) or overdiagnosed. Thus of millions of average-risk asymptomatic women having breast irradiation screening each year, only 1 in 10 000 really benefit.”  They put the risk of having breast cancer found on xray screening at 2% over 10years ie 0.2% per year in a 50year old women, and her 20 year risk of dying of breast cancer at 1% . Most women with screen-detected breast cancer have not had their life saved by screening.  

 Dr Susan Love a leading USA professor of surgery would like to see “less emphasis on screening and more focus on cancer prevention and treatment for the most aggressive cancers, particularly those that affect younger women. Roughly 15 percent to 20 percent of breast cancers are deadly. And even with screening, bad cancers are still bad. ” 

Dr Cornelia Baines an emeritus professor at the University Toronto affirms that “the benefit (of breast xray screening) is much smaller in terms of avoiding death than is the harm arising from over-diagnosis and unnecessary treatment for breast cancer, to say nothing of increased rate of mastectomy associated with screening.These issues are not widely known to the general public. ”

 2. Similarly, a massive study from  Georgetown University Washington DC, concluded that  “Biennial screening from 50-74 reduces the probability of breast cancer death from 3% to 2.3%. Screening annually from 40 to 84 only lowers mortality an additional one-half of one percent to 1.8% but requires substantially more mammograms and yields more false-positives and over-diagnosed cases. Decisions about screening strategy depend on preferences for benefits vs. potential harms and resource considerations”.

 3. A pan-USA consortium found that in 170 000 USA women followed with xray screening annually for 10 years, more than half of women received at least 1 false-positive recall, and 7% to 9% a false-positive biopsy recommendation.

 And finally a survey of the Swedish screening mammography program since 1986 found similar outcome as in the Norwegian program: “the 4-year cumulative incidence of invasive breast cancer was -significantly higher in the screened group by 49% (982 per 100 000) than it was in the control group (658 per 100 000). Because the cumulative incidence among controls did not reach that of the screened group, we believe that many invasive breast cancers detected by repeated xray screening do not persist to be detected by screening at the end of 6 years, suggesting that the natural course of many of the screen-detected invasive breast cancers is to spontaneously regress”.

It is obvious to most when the light is switched off; and that lengthy exposure to intense sunshine damages- no randomized cotrolled trials are needed. Conversely it took millennia before most educated people recognized that neither our Earth nor Sun are the centre of the universe- and many people still do not believe in human rights..

 In contrast to eternal human need for mysticism /spiritualism promoting blind faith in deities and prayer and an afterlife, rationalists like Steven Jay Gould argue irrefutably that science and religion are incompatible non-overlapping magisteria. Even Kierkegaard had to admit this in conceding that its tough going against mainstream belief however strong and wrong the mainstream may be, even though religious belief is simply that- irrational blind faith. From the heart, not from rational reasoning.

 Search of Pubmed for “randomized controlled trials screening xray mammography” yields not a single trial. In fact the only truly randomized long trial ever conducted with modern xray mammography – the Canadian Breast Screening trial between 1980 and 1990 and comparing manual self-examination alone versus combined with xray mammography (Miller & Baines 1997) – showed that adding screening xray mammography had no impact on the rate of death from breast cancer at up to 13 years’ follow-up from entry.

This outcome has never been disproven except in the minds of those who zealously promote the $8billion a year xray mammography industry, whatever their vested interests from fundraising organizations to service providers and screening machine manufacturing countries.

There are thus at least 20 studies already published showing that screening xray mammography has no benefits compared to its many risks, for reduction in future breast cancer and breast procedures or mortality.

  So it is ethically, morally and scientifically negligent to continue to promote fearmongering  xray screening mammography without explaining to women that xray screening has no benefit for survival from breast cancer, and may in fact not just promote fruitles pain, anxiety, mastectomy and radiochemotherapy but also hasten death.

Should screening xray mammography even still be offered as a diease-mongering  choice for women ? when it is now so well proven by independent studies and expert reviewers that it offers no benefit over regular manual breast examination, but indeed offers many cumulative risks to women, at great cost to individual women and society.

The analogy is the sale of tobacco smoking and alcohol. Unlike the safe use of moderate social alcohol in private, should aggressive promotion, marketing of xray breast mammography, smoking,  alcohol and other addictive drug (like designer antidepressants and other psychotropics) consumption be allowed at all?

CANSA Breast Cancer Screening Position Statement

21 Oct 2011 neil.burman@gmail.com          this Mammography statement by the National Cancer Association of South Africa is abridged, with my comments in italics:

 CANSA Breast Cancer Position Statement   September 2010        Compiled by Magdalene Seguin Cancer Association SA. http://www.cansa.org.za/cause_data/images/1056/CANSA_Breast_Cancer_Position_Statement_(2).pdf 

Breast cancer is the leading cancer in women worldwide, with increase in developing countries due to an increase in life expectancy. According to the Globocan Report, 1,3 million women were diagnosed with breast cancer and half a billion women died of it worldwide in 2008. In South Africa the lifetime risk for breast cancer in women is 1 in 29 according to the 2001 National Cancer Registry.  It is 100 times more common in women than men from 60 years of age.

Breast cancer in males is rare accounting for 1% of all breast cancers.1 in 1,000 men- one in 928 develop it. Men with a faulty BRCA2 gene (which is related to female breast cancer as well), have a 1 in 12 chance of developing breast cancer before the age of eighty.

Breast cancer detection in South Africa                                                      Breast self examination (BSE) and clinical breast examination (CBE) are the two most important routine detection methods . They are not diagnostic (nor is any test except tissue exam) but enable further investigation if a lump is detectable. Most breast lumps are benign (non- cancerous ) but new or solitary ones need full investigation.               Ultrasound is mainly utilised as an aid to mammography in persons with suspicious lumps, thus to guide fine needle biopsies (FNB).

 If no optional facilities are available, screening by xray mammography alone, with physical examination of the breasts, plus follow-up of individuals with positive or suspicious findings, will (it is claimed) reduce mortality from breast cancer by up to one-third among women aged 50–69 years.                                    Much of the (screening if any) benefit is obtained by screening once every two to three years as recommended in eg UK..

 XRAY Mammography and Ultrasound :D eveloped specifically for breast tissue radiography, xray mammography is used as a diagnostic tool for symptomatic persons. The imaging system for xray mammography is adapted for the lowest radiation dose possible. The efficacy of mammography depends on the technical quality and the expertise of the radiologist that interprets it. Mammography screening should thus be done in institutions where effective evidence of screening has been proven.

CANSA advocates an xray mammogram every 3 years from age 35 for non- symptomatic breast screening. The scientific evidence regarding over- exposure to radiation and increased risks in early detection is increasingly established and should be approached with the precautionary principle.

 Emerging techniques in breast imaging The following techniques have been assessed globally for potential strengths and limitations as indicated below: 1. The SureTouch breast screening tool : Verified and offered by CANSA, the SureTouch screening device is affordable and small enough to be offered in mobile health clinics. It is CANSA’s aim to equip each of its six mobile health clinics with this effective and affordable SureTouch screening tool, thereby increasing the accessibility and quality of breast cancer screening services to all women in South Africa.                                                                                              Benefits of the SureTouch device include: Sensitive and accurate: The probe houses tactile sensors up to 4 x as sensitive to human touch and is clinically proven to accurately map lesions as small as 5mm.                                                        Real time palpation: Simply palpate suspicious breast lesions and receive instant images of surface stress patterns.                                                                         Objective, reproducible record: Palpation images are reproducible by different examiners, eliminating the subjective nature of a clinical breast exam.  Saves time: Prints an objective electronic record in seconds.                                     Non-invasive and comfortable: Uses a sterile disposable cover and non-toxic, non-irritating lubricant to glide over target areas.                                                           Pain- and radiation free computerised breast imaging:                                          The procedure is totally non-invasive, requires no compression of the breast tissue and uses no harmful radiation to create an image.

 2 Digital xray mammography or MRI – lower or zero dose radiation but higher in cost than xray mammography

3.Infrared thermomammography – infrared photographic  measurement of abnormal heat pattern, no harmful radiation.

4.Transillumination (near infrared spectroscopy light scanning) on infrared sensitive film with a television camera, is less sensitive and specific than xray mammography, no harmful radiation.

CONCLUSION If you’re over 35yrs in a higher risk category, regular mammograms could save your life. But evidence is increasing that routine xray screening mammography does not save lives, while increasing many risks. The risks do not apply to thermo- or Sure-Touch mammo.

SCREENING COLON IMAGING IN LOWRISK PATIENTS?

20 Oct  2011    neil.burman@gmail.com

A chiropracter asks: what is the recommendation regarding screening colonoscopy, mammography, prostate for cancers? would MD’s and DO’s get one and if so in what circumstance?

My answer:

The only link between breast, prostate, bowel, ovary and womb cancers is that these organs abut; and (unlike cervix cancer) they are genetically linked through common sex hormone influences..

Prostate cancer associates with higher estrogen and DHT levels. As for usually estrogen-dependent breasts and  breast cancer screening in low-risk breasts discussed previously, the overwhelming evidence favours no screening at all without symptoms  or risk factors. Unlike for breast cancer,  treatment for prostate cancer seems to make no difference except when there is obstruction or bleeding. For asymptomatic PRCA the rule remains: watchful waiting. Many men have undiagnosed ie asymptomatic prostate cancer at autopsy for other causes of death.

Colon cancer is different.   it is less common in women with estrogen replacement.

But unlike prostate and breast cancer where invasive screening of all lowrisk patients likely causes more harm  (including despondency) than good,  it is hard to find good colon cancer studies of asymptomatic lowrisk people that show no benefit of screening colon imaging. Studies of colon cancer imaging are inevitably by practitioners who have  a major commercial vested interest in such imaging.

But how many studies have been done comparing colon screening with no screening in patients who truly have none of the risk factors -  - heredity, meat diet, smoking, overweight, occult blood, inflammatory bowel disease, polyps, diabetes?

Few articles are against such colon screening ie rationalize or philosophises against it .

A 2011 Medscape review from a New Jersey University team concludes cautiously: “In particular, education and intervention efforts for colon imaging should be focused on patients that have risk factors eg diabetes, obesity, or are former/current smokers. This population represents a sub-group of patients who are having CRC screening at a rate lower than the average-risk population. Significant reductions in CRC incidence and mortality might be possible by providing targeted screening interventions to increased-risk individuals and by educating physicians on the importance of recommending screening to these patients even in the face of multiple competing demands”. ie it  encourages  colon screening in  increased risk individuals.  

Search of Pubmed for “incidental colon cancer at autopsy” reveals only three  studies, >20 years ago,  two in the orient.

Ueyama ea, Kyushu University, Japan in Am J Gastroenterol.1991    Colorectal carcinomas incidentally detected in 3,638 autopsied cases and inpatients  during the past 20 yr.   17 colorectal carcinomas (0.47%) were incidentally detected among autopsied patients without clinically evident colorectal carcinoma, including 2,232 males and 1,406 females more than 40 yr old. Among the 15 male and two female index subjects, six (0.33%) were detected in the first and 11 (0.60%) in the second decade. During their survival periods, fecal occult blood studies were performed in 14 cases and positive in 12 (86%); however, two of them had gastric ulcers which were responsible for the occult blood. During the recent 11 yr, six cases (0.48%) of colorectal carcinoma (four of them males; two, females) also were detected among 1,249 inpatients who were examined by barium enema and/or colonoscopy, including 816 males and 433 females, 40 yr old, or more, in the Department of Radiology. Fecal occult blood was detected in four cases (67%) before colonic investigation. Compared with 708 surgically resected carcinomas, the incidental lesions from both sources were smaller, consisted of higher percentages of Dukes’ A type, and arose predominantly from the sigmoid colon and, rarely, from the rectum. These results indicate that the prevalence of colorectal carcinoma and its predominance in the sigmoid colon have not only apparently but actually increased in Japan, apart from improved diagnostic capabilities, and that false-negative rates with occult blood tests were surprisingly low in these autopsied cases and inpatients.

 Lee YS in Cancer 1988 studied Incidental carcinoma of the colorectum at autopsy in Singapore. . . Ten incidental invasive carcinomas (two early carcinomas involving the submucosa, and eight advanced carcinomas involving the muscularis propria or beyond) of the large intestine were discovered in a series of 1014 consecutive autopsies. All occurred in Chinese aged 60 years and older, constituting a prevalence rate of about 3% in this age group. If unsuspected colorectal carcinomas in Chinese Singapore residents aged 60 years and older exist in those who died in 1984 to the same extent as that noted in this autopsy study, it was estimated that 146 additional cases would have been added to the Cancer Registry in that year. This would constitute 47.9% of the total number of colorectal cancers diagnosed in this age group in 1984. This potential contribution has to be taken into consideration in epidemiologic studies on the incidence and future trends of colorectal cancers in Singapore. Incidental carcinomas were found predominantly in the ascending colon. With more frequent use of colonoscopy, the incidence of right-sided cancers of the large bowel may be expected to increase. The current underdiagnosis of ascending colon carcinomas has to be taken into consideration when any future increase in right-sided cancers of the large bowel is observed. 

Suen ea Cancer. 1974 studied Cancer and old age – autopsy study of 3,535 patients over 65 years old, in New York from 1960 to 1970 ie a decade earlier than the above oriental studies; they showed that men had cancer nearly twice as frequently as women (40% vs. 24%); and more incidental ie less aggressive neoplasms as age advanced. The most frequent cancers were those of the prostate (12% of men), gyne (7.5% of women- breast 3%) , kidney 3.5%, and colon 5.6%.. 70% of the cancers were already diagnosed in life ie 30% were incidental findings. Cancer tended to metastasize less frequently in the elderly.  The most common sites of latent asymptomatic cancer reported by Berg et al The prevalence of latent cancers in cancer patients. Arch. Pathol 1971. in their study of 5636 cancer patients with ages ranging from the teens to over 80,were prostate, thyroid, colon, and kidney. They further emphasized that cancer of the colon and kidney were the ones most easily missed clinically. In our study, the most frequent sites of incidental cancer, among the common cancers, were prostate (incidental 67%), kidney (51%), colon (31.5%), and breast 16.6%.

And  researchers from the Universities of California, North Carolina and Harvard -  Walter ea- show in 2005  Screening for colorectal, breast, and cervical cancer in the elderly: Am J Medicine  that “characteristics of individual patients that go beyond age should be the driving factors in screening decisions… in one study -Selby ea A case-control study of screening sigmoidoscopy and mortality from colorectal cancer . N Engl J Med . 1992; .”For colorectal cancer screening, fecal occult blood testing has the strongest evidence of benefit in elderly patients, while flexible sigmoidoscopy reduces mortality from colorectal cancer by 59% .Flexible sigmoidoscopy has fewer complications than colonoscopy, with perforations occurring in less than 0.1 of 1000 examinations; .” But they did not report data on benefit of colorectal screening of lowrisk adults in terms of actual overall life extension ie reduction in all-cause mortality- which benefit has not been shown in rigorous analysis of xray screening mammography or screening blood and digital exams of lowrisk men for prostate cancer. .

Lack of significant life extension by breast and colon screening was shown by Rich and Black from Vermont USA in Clin Pract. 2000 When should we stop screening? Given a starting age of 50 years, screening throughout life has a maximum potential life expectancy benefit of 43 days for breast cancer and 28 days for colon cancer.

These 1 month extensions in life expectancy do not justify screening the entire population of older persons- surely only those of us with significant risk factors need be screened.

CONCLUSION: from the above references from autopsy series, the prevalence  of   incidental ie asymptomatic colon cancer at routine autopsy  in older deaths varies between about 0.5% and 3% in oriental and New York patients. So since I dont have any symptoms or risk factors listed, after 50 years in medicine I havent had colon or prostate imaging for a potential 4 week gain in life expectancy. I will do so promptly if I get colon symptoms.

 I tell my older lowrisk patients the dubious potential benefit of cancer screening, and the serious risks, from overdiagnosis- polyps and lowgrade cancers that might never present in lifetime, to perforation ; while explaining to them that well-patient  breast, prostate  and colon cancer screening is hugely profitable universal policy.

For non-emergency consultations and especially costly and invasive procedures, doctors and patients need reminding that it’s the patient’s choice, not the doctors’..

This brings us to one of the ethical dilemmas of medicine: when our experience, and careful sifting of the hard evidence, conflicts with conventional wisdom- which is often based on belief and vested interests- evidence slanted hy bias- surely we practitioners have both a right to express our evidence-based personal conviction, and a duty to do so. Thus we surely have a duty  to give the patient the hard evidence both for and against- be it about the power of prayer and belief, about contraception and abortion, for and against statins for mild-moderate lipidemia, or in the low-risk patient, screening mammography, prostate or colon screening.

 

 

THE EVIDENCE AGAINST XRAY SCREENING MAMMOGRAPHY GROWS AFTER 20 YEARS.

 Update 18/10/2011 neil.burman@gmail.com

NATIONAL MAMMOGRAPHY DAY 21 OCT 2011:  WORLD BREASTCANCER AWARENESS MONTH National_Breast_Cancer_Awareness_Month :                                THE DEBATE AGAINST XRAY SCREENING MAMMOGRAPHY OF LOWRISK WELL BREASTS.      MOTIVATION FOR NON-XRAY SCREENING MAMMOGRAPHY:

A medical scheme recently asked for a motivation letter for a member wanting them to fund a non-xray mammogram.

 Thinking women cannot do like a postmenopausal professor in genetics – a senior health lecturer and counsellor no less- shrug off the issue of their blind obedience to medical diktat as “not my field”, when unquestioningly undergoing invasive let alone known hazardous tests like screening xray mammography, and major therapy for asymptomatic hidden lumps, on the say-so of their doctors/ their medical scheme advisors, however great their eminence.

Safety in numbers of eminent opinions is no assurance that the collective conventional wisdom and Guidelines are correct, when such conventional wisdom is as likely as not turned on its head in a few years.

Blind obeisance without careful personal study of the evidence for and against is as foolish as taking the advice of the glib salesman self-promoter in any costly and therefore risky investment, be it in health as in finances, property, a motor car, costly other assetts, a job or a glib new lover.

This week Dr Joe Mercola  highlights the latest reports from USA, the  double disaster of xray mammography increasing the risk of breast cancer in women with a familial risk; and more than half of women xray- screened regularly  over 10 years receive at leat one false-positive recall- with all the extra breast  procedures, and upset, that that entails.

Look at what happened to USA and UK-Europe when they blindly followed the advice of the snakeoil vendors the Bush-Blair Gang in invading Iraq in 2003, and listened to the advice of  their self-enriching financial gurus and bankers that led to the demise of balanced national budgets and the western capitalist system in 2008. The USA has achieved the unthinkable, being downgraded to the most bankrupt country, worse than many southern European nations now are, because Bush for the benefit of his cronies abandoned the common-sense balanced budgets reducing national debt insisted on by Clinton, and plunged USA into multitrillion dollar debt that future generations of taxpayers have to pay. .

In women without breast symptoms or familial risk of breast cancer, regular analysis of evidence  to April 2011  on the pros and cons of SCREENING xray mammography ie breast imaging, showed increasingly the risk but no benefit of such xray screening.

The anonymous Wikipedia review outlines the violently opposing views of the screening mammography issue – from sceptical independent analysts, and from the zealous majority, the lucrative vested-interest screening xray mammography - breast surgery industry, who claim shortterm benefit from emotive early diagnosis and treatment. .

It is a sign of the paradigm shift in medical thinking and dogma when a leading medical school eg Tygerberg Hospital no longer accepts women with a palpable breast mass referred for diagnosticxray mammography, but instead first sees them for careful history, examination and fine needle aspiration biopsy.

Last months’ leading Radiology journal features a debate between the two opposing viewpoints;  ; as does a recent medscape debate; http://www.medscape.com/viewarticle/734977 with Heaod of Radiology  Daniel Kopans at  Harvard spearheading the xray mammographers and breast surgeons argument – Just the facts: mammography saves lives with little if any radiation risk to the mature breast.

and Dr Cornelia Baines from Toronto University joins the European and USA critics of routine screening in exhaustively analysing why so many studies convincingly confirm the original Canadian Breast Cancer Screening Study Miller, Baines ea 2004  evidence against routine xray screening – xray screening did not reduce breast cancer mortality after 13years when compared to routine clinical breast examination;

- and the 2009 recommendation of the US Preventitive Task Force to limit recommendation for xray screening mammography to well women only from age 50 years onwards, and every 2 years not annually. Since April 2011 at least nine more authoritative independent scientific papers listed below detail why routine screening xray mammography of well breasts (in women not at known increased risk) gives no longterm meaningful reduction in either invasive breast cancer or mortality. In fact, there is evidence that such repeated breast trauma- crushing, irradiation, surgery and therapy -  actually increases risks of mastectomy, breast cancer and mortality after 10 years, just as oral xeno-hormone replacement therapy may.

The Dec 2010    UK NHS recommendation brochure  by contrast  limits screening mammography to women over 50yrs up to 70yrs, and only every 3 yrs. Thus the UK recommends only about 7 screening mammograms over her lifetime for well lowrisk women. This contrasts with the pressure on USA women to have screening from age 40 years annually ie four times as many as in UK- about 30 screening mmmograms over her lifetime. …

The latest published study, from the University of California no lessconfirms their earlier 2007 study that the more costly computer-aided detection was not associated with higher breast cancer detection rates or more favorable stage, size, or lymph node status of invasive breast cancer. CAD use during xray screening mammography in the USA is associated with decreased specificity but not with improvement in the detection rate or prognostic characteristics of invasive breast cancer. When previously well women are followed up over decades with xray screening mammography, objective studies of at least thirteen first-world countries – Australia, U.S.A, Norway, Denmark, Sweden, Italy, France, Switzerland, Netherlands, Belgium, U.K, Scotland, Northern Ireland, and Ireland – show no patient benefit from such screening xray in reducing breast surgery, advanced breast cancer, mastectomy, or mortality,.

Such evidence and argument against screening of the asymptomatic male without familial risk has been widely accepted for prostate cancer screening. Why are women with no known increased risk perversely all irradiated about 15 to 30 times from their 40s?

And a new study from Minneapolis finds that lowrisk women ie without dense breasts, symptoms or family history need not have screening xray mammography more than every 3 -4 years. The Mayo Clinic lists simply the obvious risks of xray mammography.

There is yet another obvious reason – conveniently not mentioned by researchers and xray mammographers - why screening xray mammography may miss cancers ie give false negative results: because adult female bosoms are obviously threedimensional, not flat like health mens’.. But xray mammography (unlike CAT or MRI scans) is done in only two – the vertical and lateral planes.

Unlike eg the limbs, spine, chest and head, globular female breasts cannot be xrayed meaningfully in the anterior-posterior plane superimposed on the chest, and thus small breast cancers close to the lateral chest wall or the armpits cannot be xray imaged. By contrast, examination with the hands, with thermography, with ultrasound, MRI and now with (eg SureTouch) mechanical pressure transducers check for suspicious lumps in three dimensions ie also in the anterior-posterior plane.  

3D breast xray imaging is becoming a reality . But it still relies on xray irradiation.

Research PhD Geneticist Dr Natalie Bjorklund-Gordon pleads for altenatives to xray screening mammography, she explains exquisitely why she will not have xray screening mammography (let alone screening colonoscopy) . She pleads for nonxray safe and sure technology for screening.  

But review  shows that proven alternatives are available here and worldwide. Thermomammography is now highly evolved over the past 40 years; and mechanical tactile breast mapping over the past decade.

As these on-line reviews detail, is it ethical let alone cost-beneficial to promote routine screening mammography on women at any age who do not have probable breast cancer?

But for those well women who desire screening mammography for peace of mind, infrared thermomammography is the physiological gold standard that may pick up precancerous increased bloodflow years before a cancer mass is detectable by other ie anatomical mammography methods so as to allow non-interventional preventative steps;

while mechanical tactile mammography (eg SureTouch) as recommended by the Cancer Association of RSA is the safe non-invasive anatomical screening tool of choice.

Yet Curves Tokai is still promoting the pernicious offer of free membership of curves upon production of a recent mammogram – without bothering to warn of the major potential hazards of screening xray mammography.  . So long as the Curves empire is openminded ie accepts the alternatives to xray mammography eg MRI, thermography and Digital Tactile Mammography

For anxious women, third party funders should pay for these safe and at least as specific and sensitive non-invasive investigations (rather than for invasive xray screening mammography at two to four times the cost).

In conclusion: all thinking women hold the primary responsibility for their own and their families’ health. It therefore behoves every woman let alone man to take responsibility for prevention when young for their future health. Like Dr Bjorklund-Gordon, they have to make informed decisions about the risk:benefit of having invasive screening like xray mammography and biopsies – just as they have to about their education, careers, financial management and relationships- about their health choices including screening.

Recent refs.

  1. Oct 2011 Utzon-Frank N, Lynge E ea Cancer Epidemiol.Balancing sensitivity and specificity: Sixteen year’s of experience from mammography in Copenhagen, show that after 14 -16 years of xray mammography every 2 years, the incidence of new breast cancers detected at 14-16years actually rose by 50% compared to in the first 12 years.
  2. Sept 2011 Junod Zahl ea in Investigation of the Apparent Breast Cancer Epidemic in France show 8-fold increase between 1980 and 2000 in the number of xray mammography machines in France. Opportunistic and organised screening increased over time. In comparison to age-matched cohorts born 15 years earlier, recent cohorts had adjusted incidence proportion over 11 years that were 50 (23-76)% higher for women aged 50 to 79 years. Given that mortality did not change correspondingly, this increase in adjusted incidence was considered an estimate of overdiagnosis. Breast cancer may be overdiagnosed because screening increases diagnosis of slowly progressing non-life threatening cancer and increases misdiagnosis among women without progressive cancer. We suggest these effects could largely explain the reported “epidemic” of breast cancer.
  3. Sept 2011 Jorgensen Keen & Gotzsche at the authoritative Cochrane Centre ask Is xray mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality? They point out that the original Swedish Two-County Trial was the most optimistic and pivotal for the introduction of screening, but subsequent trials of higher quality found smaller effects...
  4. Sept 2011 Suhrke P, Gøtzsche PC, Zahl P ea BMJ note in Effect of mammography screening on surgical treatment for breast cancer in Norway: that the aim of screening xray mammography is to reduce surgery and deaths. But in 35 408 women aged 40-79 with invasive breast cancer or ductal carcinoma in situ treated surgically from 1993 to 2008, xray mammography screening in Norway was associated with a noticeable- 70%- increase in breast cancer surgery in women aged 50-69 (the age group invited to screening) and also an increase in mastectomy rates. Although over-diagnosis is likely to have caused the initial increase in mastectomy rates and the overall increase in surgery rates in those screened, the more recent decline in mastectomy rates has affected all age groups and is likely to have resulted from changes in surgical policy. 

5.  Sept 2011 Haukka J, Autier P ea. University of Finland examine Trends in Breast Cancer Mortality in Sweden before and after Implementation of Mammography Screening. : Incidence-based mortality modelling comparing the risk of breast cancer death in screened and unscreened women in nine Swedish counties suggested a 39% risk reduction in women 40 to 69 years old after introduction of mammography screening in the 1980s and 1990s. Without individual data it is impossible to completely separate the effects of improved treatment and health service organisation from that of screening, which would bias our results in favour of screening. However, our estimates from publicly available data suggest considerably lower benefits than estimates based on comparison of screened versus non-screened women. 

 6. Aug 2011 Int J Cancer. Hofvind S, Graff-Iversen S. ea at the Cancer Registry of Norway- dissect Breast cancer incidence trends in Norway-explained by hormone therapy or mammographic screening? A decline in breast cancer incidence has been observed in several countries after 2002. Reduced use of menopausal hormonal therapy (HT), as a consequence of the publication of results from the Women’s Health Initiative, has been argued to be the main reason. the interpretation of breast cancer incidence trends in Norway from 1987 to 2009 is complicated because the xray breast screening program was introduced during a period with increasing HT use. Both factors likely contributed to the observed trends, and the role of each may vary across age

7. August 2011 Professor of Surgery Michael Baum from University London has argued for years that Breast xray screening should be scrapped.

 8. August 2011 Fenton JJ, Barlow W E ea; J Natl Cancer Inst.Breast Cancer Surveillance Consortium. University of California,examined the Effectiveness of computer-aided detection CAD in community mammography, concludingCAD use during film-screen screening mammography in the United States is associated with decreased specificity but not with improvement in the detection rate or prognostic characteristics of invasive breast cancer. http://www.ncbi.nlm.nih.gov/pubmed/21795668

9. August 2011 Autier P, Gavin A. ea studied Advanced breast cancer incidence following population-based mammographic screening : Breast cancer mortality is declining in many Western countries. If mammography screening contributed to decreases in mortality, then decreases in advanced breast cancer incidence should also be noticeable. They assessed incidence trends of advanced breast cancer in areas where mammography screening has been practiced for at least 7 years ie Australia, Italy, Norway, Switzerland, Netherlands, U.K, U.S.A, Scotland, Northern Ireland, Age-adjusted annual percent changes were stable or increasing in ten areas (APCs of -0.5% to 1.7%). Thus in areas with widespread sustained mammographic screening, trends in advanced breast cancer incidence do not support a substantial role for screening in the decrease in mortality. http://www.ncbi.nlm.nih.gov/pubmed/21252058

10.   July 2011 Autier, Vatten ea in BMJ in Breast cancer mortality in neighbouring European countries 1986-2000 with different levels of screening but similar access to treatment compare Norway with Sweden, Belgium with Netherlands and Eire with Ulster, The contrast between the time differences in implementation of xray mammography screening and the similarity in reductions in mortality between the country pairs suggest that screening did not play a direct part in the reductions in breast cancer mortality. http://www.ncbi.nlm.nih.gov/pubmed/21798968

And finally

11. June 2011: PhD research clinical scientist geneticist Dr Natalie Bjorklund-Gordon details exquisitely “why I am not having screening mammography” (or screening colonoscopy). http://www.science20.com/selective_genetics/why_i_am_not_having_screening_mammogram-79776

ARE NICOTINAMIDE AND NICOTINIC ACID-NIACIN IDENTICAL?

neil.burman@gmail.com

a pharmacist asks: surely niacin and nicotinamide are the same?

But they are not, although they are both vitamin B3. But nicotinamide has an amide NH moiety  substituted for one oxygen molecule in nicotinic acid, hence nicotinamide is an antioxidant, nicotinic acid is not.

in the food chain, both occur in balance. Niacin metabolizes to nicotinamide and NAD. It doesnt work the other way round, so nicotinamide has no benefit on lipidemia.
 
as supplements the two different forms of vit B3 have major different effects. In a multisupplement we put both in ~ RDA dose.
But for pharmacological benefits we use up to 100 fold  higher doses eg over a gm of niacin for lipidemia or a few hundred mg of nicotamide as part of an antiinflammatory or antidiabetic combo.

This table (derived from Wikipedia, from Pubmed and from the Linus Pauling Institute website of Oregon State university) summarizes the biochemical and clinical differences:

EFFECTS OF THERAPEUTIC DOSES WELL BELOW 3GM/D

property NICOTINIC ACID NICOTINAMIDE
     
formula C6H5NO2 acid C6H6N2O amide
molecular wt 123.1 122.1
lipids-          LDL, Lp(a), Tg, fall significantly no effect
          HDL rises significantly no effect
Anti-inflammatory   yes -anti-acne, skin whitener, antiosteoarthritic.
psychiatric  antidepressant anxiolytic
sirtuins   activates        (anti-Alzheimers)
vasodilator yes no
coronary artery disease reduced. reduced
deficiency pellagra only if nicotinic acid deficient.
cancer reduced. reduced
antidiabetic   significant; antioxidant
AIDS – HIV infection slowed  
TOXICITY at therapeutic doses    
itch ++ . no
flushing ++ at >30mg/d if dose > 3gm/d
can cause jaundice ++ . liver protective
can cause gout yes no

THE SCREENING MAMMOGRAPHY TSUNAMI

neil.burman@gmail.com 

The past year has seen not just catastrophic oilleaks, earthquakes  and thus marine and radiation disaster  accross the world, but also in Big-Business -driven campaigns to promote invasive radiation  screening mammography. Is the Disease-industry-driven screening   xray mammography tsunami fearmongering    to inflate the $trillion cancer industry ?

A tsunami is an overwhelming and non-tidal deluge. What does the screening mammogram xray deluge  for ever-younger  women bode for their later years?

Any intelligent consumer, not just a  specialist for 40 years, should  look very critically at all technology marketing  and products, and ignore most as unjustified.

Winifred Cutler from the Athena Institute writes this month: it is claimed that screening xray mammography and early treatment of silent breast (pre)cancer has greatly reduced  breast cancer mortality. But she points out that such mortality has also fallen in unscreened women, and given the incidence of overdiagnosis, “the adjusted mortality reduction that can be attributed to widespread  xray mammographic screening may be even more modest than reported by Kalager and colleagues: instead of the 7.2 reduction per 100,000 person-years that they report, a number somewhere between 5.99 and 5.54 should be compared to the 4.8 reduction per 100,000 person-years found in non-screened women. Hence, between 80% (4.8/5.99) and 88% (4.8/5.54) of the reduction in mortality may be attributable to issues other than mammogram screening”.

Another paper this month   reviews “Antidepressants and breast and ovarian cancer risk  and researchers’ financial associations with industry” – concluding that “Researchers with industry affiliations were significantly less likely than researchers without those ties to conclude that ADs increase the risk of breast or ovarian cancer. (0/15 [0%] vs 20/46 [43.5%] (Fisher’s Exact test P = 0.0012).”  ie in studies independent of AD manufacturers,  there is strikingly significant increase in breast cancer risk in those on antidepressants. With all the focus on the overblown risk of womens’ cancers, and the oft-reported discomforts and recalls from  screening xray mammography, no wonder that depression and breast cancer risk may be increased not just by stress (including the dreaded annual mammogram)  but more so by estrogenic ADs .

In view of the controversies about both necessity for well-breast screening, and patient complaints and cost-benefit doubts about xray mammography,  we consider  two of the options that radiologists dont  generally offer – thermography recommended by a recent patient with her thermography report, and tactile pressure-transducer  mapping recommended and used by CANSA the Cancer Association of South Africa, and the breast clinic at Newcastle-on-Tyne University.  

Both equipment technologies  are approved  in eg USA/ UK/ Europe/ Australia, and have been screened and not disapproved by regulatory authorities since the latter have no experience of such, and they are approved overseas, and there are no usage hazards, and as yet no standards locally, and no claims are made about their efficacy for diagnosis, prevention or treatment.

Thermography is used in clinics around South Africa; while pressure transducer tactile breast mapping is recommended and offered by CANSA for the poor in the main centres. In Gauteng one  radiologist does ultrasound followup in the ~10% of breasts where cancer cannot be confidently excluded.

There are obviously at least three major separate issues:

1.REAL RISKS OF COMMON CANCER?  Is the risk – incidence and mortality- of presymptomatic cancer in well patients without genetic risk of developing breast or prostate cancer high? and does early detection of presymptomatic breast or prostate cancer in patients not at high risk do more good than harm? Careful analysis of all available unbiased data suggests not- in fact such early diagnosis possibly  does more harm than good. 

2. RISKS OF REPEATED INVASIVE XRAY SCREENING: are  the risks of breast cancer increased by repeated xray screening?

3. IS ANY MAMMOGRAPHY METHOD TRULY SUPERIOR OR MORE RISKY?  Are the alternative screening mammography options- MRI, tactile mapping, thermomammography,  ultrasound- significantly different from each other and from invasive xray compression  mammography in risks and in sensitivity/ specificity? The evidence suggests that thermomammo, MRI and tactile mapping are safer and more sensitive and specific than xray mammography, and more sensitive than ultrasound as primary screening.

BACKGROUND:     Screening in medical practice thirty years ago used to refer to xay fluoroscopy – viewing through a fluoroscope screen- as is done of passengers at airports; but now refers to any preventative ie screening tests for silent undetected early disease. The most validated screening for cost-benefit – apart from taking a complete history- remains objective ie electronic bloodpressure monitoring.

However, is there still  justification for ever exposing younger healthy tissue- especially the thyroid, breasts and gonads- to repeated preventative invasive  xray “screening” under any circumstamces including for mammography and bone densometry? Especially not children, and especially not well younger (pre or peri)menopausal women  with already fluctuating endogenous estrogen dominance, who now with safe lifestyles have an average life expectancy ahead of them of perhaps 40 years. And when so many older middle-aged women simultaneously have been exposed needlessly to long-known carcinogenic smoking, alcohol and other oral estrogenics- soya, psychotropes, estrogens and progestins- recent use of oral contraceptives increases the risk of breast cancer. 

 The ongoing argument for and against screening is hotly debated by specialists opposed by the vested interest of the Screening Industry.  

XRAY MAMMOGRAPHY:    A Sherbrooke University Quebec paper published in 2011  seems unique- Irradiation (30Gy) of normal mouse tissue increases by some 30fold  the invasiveness of subsequent subcutaneously injected induced mouse breast cancer cells after 6 weeks  . There is nothing like it before on Pubmed nor apparently on Google – that recent normal-thigh irradiation vanquishes cancer resistance. This may explain why  breast cancer incidence, and mortality,  may be the same, if not higher  than in non-screened women after 10 years of   regular xray screening mammography of healthy breasts (the Norwegian and Danish studies of last year- see below) . The mouse irradiation study tries to simulate with one-off irradiation  the situation in women who have breast cancer removed and then a course of fractionated radiotherapy – which may eradicate most existing cancer but promotes fibrosis, but may promote  growth of metastatic   cancer cells into surrounding previously cancer-free subcutaneous tissue. This correlates with the shrunken hard breast we see in women who have had breast cancer excision and then breast radiotherapy.

Whether this applies to repeated (bi)ennial  screening xray mammography of “well” breasts over many years  with perhaps a few milliGy of diagnostic xray each time remains to be clarified.   Ruth Kleinerman’s followup of children does suggest possible risk,  that modest irradiation for diagnostic or therapeutic purposes with 0.1 to 0.7Gy increases breast cancer risk up to 2.5fold a decade to fifty years later.   This especially when the breast sceening industry claims that breast cancer lifetime risk is already above 10% eg 1 in 10, and increases with aging.

And correlates with work 30 years ago -Brian Henderson ea San Fransisco -that even ‘modest’ dose of another indisputable secondary carcinogen – oral ie megadose xeno-estrogen-progestin eg PremPro – started soon after menopause- progressively increases breast cancer risk when continued ie > 1500mg premarin for much more than a decade . .

Are women   reaping the harvest of liberal combined (post)menopausal oral (in North America, mostly (xeno)-estrogen therapy) – ERT – since the 1990s – ie to women born after WW2 – with liberal screening mammography?  - “a social obligation” according to xray-screened British women recently canvassed by Frances Griffiths ea .

Have either of these universal prescriptions for women ever been justified by independent longterm (ie well over 10 year) cost-benefit trials? since the 1980s Canadian Breast Screening Trial (1990 Brian Miller ea  )  cast doubt on the benefit over 5 years of  Xray screening mammography . . 

 A practicing USA radiologist like Dr Jeff Dach argues realistically against all such screening based on the evidence.  . He says, ‘just switch off the screening imaging machines, stop calling ductal carcinoma in situ of the breast a cancer.’  This may enrage radiologists offering screening xray mammography, and breast surgeons specializing in early breast cancer surgery.

IS RISK INCREASED BY XRAY SCREENING?  OVERDIAGNOSIS BY XRAY MAMMOGRAPHY SCREENING?          Despite numerous modelling studies trying to theorize – model  the safety of xray mammography, eg from Netherlands and Canada , a Spanish study has just confirmed that breast cancer is overdiagnosed by screening mammography by almost 50% in younger women so screened.  This bears out the observed greater Danish decline in overall mortality after about a decade  (2%) in those not screened than in those screened (1%) by Jorgensen Zahl and Gotzche;     and the lack of decline in incidence of breast cancer over the decades from screening mammography in the English-speaking continents, Sweden and Norway,  documented by Jorgensen and Gotzche. These studies contrast with other studies quoted by the mammography industry. Each group disputes the statistics of the other. .

The recent review in NEJM by Kalager ea of screening xray mammography in Norway similarly showed that such repeated breast screening irradiation if anything saves 1 in 40 000 lives from breast cancer, and barely reduces the longterm risk of breast cancer- contrary to what the dominant Xray Screening Industry would have us believe the past 20 years. .

But as Welch’s accompanying editorial on Kalager’s Norway study points out,  (and sent by the South African Menopause Society January 2011 email Menopause Matters newsletter) “The risk of a 50 year old woman dying from breast cancer in the next 10 years of her life is 0.4% (or 40 per 10 000) – this calculation includes (xray) screening. Put in the obverse frame of reference 9 960 per 10 000 will not die from such cause. Screening contributes 10% to this survival so without screening 9 956 women will not die. The number of lives saved by screening is thus 4 per 10 000 women per 10 years of screening. Using “numbers needed to treat” 2 500 women would need to be screened for 10 years to save one life. This is the benefit of screening. The harms are what happen to the 2499 women who are screened that do not die. Depending on screening techniques roughly 1 000 of the 2 499 (ie 40%) can anticipate a false-positive  and some sort of recall for further screening  This number rises with the frequency of mammography and is here calculated on screening every 2 years. Over-diagnosis and over-treatment is more sinister and would occur in 10 of the 2 499 survivors. This is needless (iatrogenic) treatment of a condition that was never going to bother them. False-positive diagnoses and over-treatments are the harms of screening.”

Is there any  objective evidence for the marketing slogan of the American Radiological and Breast Surgeons’ Associations- and the Curves International website-  that Screening Xray Mammography Saves Lives – in order to promote the $8billion a year xray screening mammography industry and the $trillion a year cancer industry?

And it needs to be stressed that the above concerns about screening mammography are directed at XRAY mammography, since due to heavy marketing and promotion,  Xray mammography is the only mammography method in use in all papers and studies of widespread primary screening of well breasts in women not at high risk from eg family history, previous cancer or already having breast lump or bleeding or pain.

It may be asked again: what male doctor would have biennial let alone annual crush xray imaging of his testes from age 40years to reduce his theoretical risk of silently developing testicular cancer, even if the hypothetical risk were 1 in 10?

THERMOGRAPHY:    A practicing academic gynecologist speaks for thermomammography from good  experience for years. Whether his esperience and opinion is  more or less valid that that of breast surgeons  who claim they can run and report xray mammography machines without a radiologist  is as usual a matter of hotly divided opinion.

 Far more important is that recent trials from Cornell , Cambridge UK and Shanghai   universities speak for the comparable effectiveness of thermography .

COMPUTERIZED TACTILE PRESSURE TRANSDUCER BREAST MAPPING  has evolved over the past decade, with applications in prostate and colorectal cancer mapping heavily funded by US Govt agencies. It ( computerized palpation tactile pressure mapping of breasts eg SureTouch) has been validated by academics such as Prof Cary Kaufman  and in controlled studies, at least eight the past decade  eg at the Necastle on Tyne Breast Clinic by Prof Clive Griffith and team (paper under peer review by the British Journal of Surgery). A recent abstract from Griffith(2009) describes study of 137 patients at a UK NHS breast clinic, 66 of whom had palpable breast masses. Seventy-seven of these were chosen at random to have a SureTouch examination in addition to CBE. Use of SureTouch reduced the percentage of missed lesions by senior and junior surgical trainees. The reproducible reports allowed efficient review by examiners with various levels of experience. Authors state that SureTouch imaging improved patients’ safety in breast clinic and likely had a role in the training and assessment of surgical trainees.

All the above options are now accepted in many western countries including South Africa, for both screening and diagnostic breast imaging, since the evidence  supports each of the options.

DEFINITION OF WHAT CONSTITUTES OPTIONS FOR MAMMOGRAPHY:   It is common sense that equipment methods involving the prefix/suffix gram eg ECG/ EKG/EEG/ spirogram/ renogram/ gramradio  often dont involve xrays. Equally, there are many established useful reliable alternative types, options for imaging the heart/lung/ breast. Neither the pre/suffix ‘gram’ nor the prefix ‘mammo’ are exclusive to the xray breast image, there are many established comparable modern breast imaging techniques from physiological- thermomammography which reflects temperature ie bloodflow,  – to anatomical eg xray, ultrasound; magnetic resonance; and the past decade to computerized palpation tactile  pressure mapping (eg SoftTouch). This is despite van Steen and Van Tiggelen’s semantic  illogic  in regarding only xray breast imaging as mammography in their 2007 Belgian History of Mammography.   Already in 1999, the Dutch used mammography interchangeably for both xray and ultrasound screening.  But the earliest apparent Pubmed reference to ultrasound mammography is in 1982. .

RISK OF BREAST (AND PROSTATE) CANCER: it is common cause that in a first world population- where most die of “natural” degenerative aging diseases rather than classic malnutrition, plagues, exposure and violence -  these cancers cause about 4% of all deaths. But most sufferers do not die from these cancers. Hence their clinical occurrence over a lifetime may be around 10% risk ; although silent – never suspected- cancers may be found in far more people at autopsy. .

With routine repetitive xray mammography screening, the annual risk of breast cancer detection is generally reported  to be about 6 per thousand.

But Winifred Cutlers’ influential Athena Institute group from USA and Switzerland recent study Breast cancer in postmenopausal women: what is the real risk? concluded that regular xray screening of well not-at-high risk breasts, in the 18 published major studies without obvious vested interest bias involving over a million women screened, the annual incidence is more like 1 in a thousand. Her group questtions the bias, data massage of SEER statistics to inflate ie fearmonger. They thus question the cost-benefit of repeated xray screening of all older women from midlife to find 1 silent cancer in every thousand women- many of which cancers may be overdiagnosis since without intervention many will never present clinically diuring lifetime..

But it is also common cause that, apart from those with strong genetic risk (at least 2 close relatives who get one of the five hormonal cancers young ie prostate, colon, breast, ovary and womb),  the risk of cancer lifelong may be 10% or less since without screening, many never present during lifetime and are found incidentally at autopsy. There are many putative avoidable – preventable- causes: obesity, diabetes and bad food choices; and drugs- alcohol; sugar; smoking; aspartame; high cortisol (stress, lack of exercise), and oral estrogenic drugs like unfermented soya, the birth control and hormone therapy pills,. The risk of cancer subsides once these risk factors are minimized – this applies even to the familial cancers- eg after more than 5 years off oral birth control or sex hormone therapy. All diabetics- and all who stay overweight, or have raised cholesterol (mostly caused by insulin resistance) – should take the best preventative all-purpose prescription drug there is, the natural plant extract-  metformin- in appropriate tolerated dose- as well as abundant all-system-protectant antioxidant insulin sensitizer nitric oxide promoting eg vitamins, minerals, biologicals including fish oil; and appropriate human HRT. .

So the only women who justify early and ongoing screening for breast cancer may in fact be those who are at high risk from the above factors; and those who want to use appropriate HRT. For such women, even if if they have no breast symptoms or lumps, thermomammogram and/or tactile breast imaging (SureTouch) screening may arguably  be started young since they are at least harmless, to indicate whether there is need for further screening with ultrasound, xray, MRI etc. . .

Obviously the (Xray and thermo- and Tactile mapping and ultrasound and MRI) mammography machine suppliers and users are not going to fund a head-to-head comparative trial of the five methods . But if we collaborate as Griffith’s Newcastle-on-Tyne group did in an observational study ie recruiting enough women to have two or more of the mammography methods each time they elect to have screening, with screening staff blinded to what is suspected and shown on other and previous mammograms, and have central co-ordination – registration and independent collation- of results, we will soon have answers, as was invaluably shown without error in eg the major longterm Nurses Study.

With already available statistics, it will not take statisticians long to calculate how many women – maybe as little as 100 in each set- will need to have at least a preset minimum of at least two different mammography options, ideally say a year apart for baseline comparison and standardization.. This will be as simple as the Groote Schuur Hospital evaluation of the quantitative ultrasound bone risk system versus xray bone densometry in over a thousand women reported in 2009-  it showed equivalence.

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

update Feb 2011: WORLD CANCER DAY DOES NOT MEAN WORLD INVASIVE CANCER SCREENING:   the 2010  World Cancer Day email from the South African Medical Association  claims that “People should get tested by means of screening, it is a simple test that will identify if an individual have an unrecognised disease” ?

Where is cancer screening simple ie no invasive and technological cost? And without false negatives? Even faecal occult blood screening is both distasteful and thus anything but simple to many patients, requires some skill in interpretation, and the test kit has a cost. This SAMA message sounds like the Curves- Breast cancer Industry’s mantra slogan that Xray Mammography Saves Lives?   

 The huge problem is to get people to report and investigate SYMPTOMS, bleeding, bowel changes, lumps promptly.  

 For SCREENING of the well ie those who dont already warrant diagnostic tests due to symptoms or family history-  the definitive diagnostic imaging screens- of cervix,  prostate, colon and breast  –  are anything but simple,   non-invasive , low-cost tests  .   Except in the small minority who have a compelling family history of any of the five interlinked genetic  (breast, womb, ovary; colon; and prostate) cancers, prostate  & breast screening  of the well for early diagnosis of asymptomatic cancer have not proven to make significant difference in long term health let alone survival except create more worry & discomfort when positive?  

Unlike the commonest medical degenerative disease of adults-  vascular disease, hypertension- even breast cancer, the most feared amongst  non-smoking women, is not that common- as the South African Cancer Association says, only “1 in 29 ie 34% of women will present with breast cancer during her lifetime” – not 1 in eight as diseasemongers would have women believe. And “cervical cancer will be diagnosed in 1:35″. And prostate cancer in “1:23 men during lifetime” and  ”one in 97 South African men is at risk at getting colorectal cancer while the rate for women is one in 162 “. And of course these risks are far lower in those who do not have bad family history and lifetyle. So the benefit of invasive screening is debatable, the risk of cancer is low in those who live safely, who know they do not have a bad family history or develop symptoms.

 Whether colon imaging (as opposed to faecal occult blood FOB screening) for preclinical diagnosis is any better at truly reducing morbidity and mortality  from colon cancer in low-risk well people is truly better than breast/ prostate screening remains to be validated in the same way  that 10 year retroanalysis has shown up the zero longterm benefit- if not more harm-  of xray screening mammography    

The US Preventative task Force study claims  15% reduction in colon cancer mortality from FOB screening – but all such data from the USA and its trading partners is so  notoriously tweaked to favour diseasemongering , can one believe any of them? Mainstream North American specialists who promote  screening scopes on all  well people naturally believe it is lfe-saving  -  but does it benefit the not-at-risk adult overall except the Screening Industry?  

For universal colon screening, where are objective colon screening studies like the recent Scandanavian breast studies that look at at least 10 year outcomes in the well low-risk population undergoing screening versus the population screened only because of symptoms?   The Wiki review of cancer screening pointedly highlights clear cancer screening benefit only for those at increased risk – which is by definition no longer primary screening for all, only for a small minority.  This seems to be a balanced rational view. Repeated cervix cancer screening is hardly cost-beneficial for the lifelong monogymous couple or ( careful olygamous) woman.

RADIATION DOSE FROM SCREENING XRAY MAMMOGRAPHY OF 50 000 WOMEN TO SAVE MAYBE ONE LIFE

Posted on November 24, 2010     A still practicing radio-oncologist retired professor  writes:

 the new study of  imaging techniques was interesting   MEASUREMENT OF THE RADIATION DOSE AND ASSESSMENT OF THE RISK IN MAMMOGRAPHY SCREENING FOR EARLY DETECTION OF CANCER OF THE BREAST, IN ISRAEL.” by Broisman ea 2010.

“I think (xray) mammography needs to come from a request from a physician following clinical history, i.e risk factors, family at risk, or if for some reason genetic screening found BRCa1 or BRCa 2 genes, or a clinical exam suggests a lump;

Patient insistence may be OK, given informed consent about the controversy about different methods, benefits and risks.

Screening xray mammography implies Xraying all females of a population “at risk”.

 Early detection is based on physician and patient related factors, I would think.

Ben

By contrast, the evidence validating breast screening thermography  – recommended by eg a practicing gynecologist -  has been increasing for fifty years;  and for those who want screening when well, has been reported as a physiological screen with comparable high sensitivity and specificity  (as compared  to anatomical imaging- static xray or ultrasound or MRI or SureTouch tactile devices ) to pick up premalignant hyperperfusion risk about 8 years earlier (than xray mammography)..

In fact, as Dr Kaunitz points out  recently,  from the Norwegian study,  “decline in mortality attributed to screening alone may be as few as 2 deaths prevented/ 100,000 women screened[3]         ie xray mammography screening may save as few as 1 per 50 000 women screened. “

This is indeed a far cry from mammographysaveslives,  when 50 000 women with apparently well breasts   are  denied full knowledge of the actual risks and nett benefits, and driven by fearmongering   to have their breasts crushed and irradiated for decades  -  to  save possibly one  life.

 

UPDATE: SUPPLEMENT CALCIUM PHOSPHATE & VIT D3- NOT BISPHOSPHONATES – FOR OSTEOPOROSIS. BISPHOSPHONATES ARE LONG-PROVEN CRIMINAL FRAUD.

neil.burman@gmail.com  

The calcium phosphate  imbalance – hyperphosphatemia and hypocalcemia and  acidosis – of chronic renal failure causes havoc on bones and circulation, and can be considerably mitigated by supplements with dolomite (CalMag)  – (NOT aluminium)- and vigorous vitamin D3,  and timely dialysis and transplantation. .

But apart from rickets and renal failure, IATROGENIC PHOSPHATE DEPLETION by antacids is a perhaps-forgotten hazard of chronic antacid ingestion : dozens of papers on Pubmed since the early 1970s to the 1990s attest to the common problem even in adults outside hospital.  The authoritative University of Oregon website  sums up the need: the recommended daily  phosphate allowance RDA for adults is about 700mg (up to 1200mg in pregnancy) – but the safe upper limit is at least  3000mg/day.

The common causes of adult chronic phosphate deficiency include (apart from food- soil phosphate depletion that blights crops; anorexia nervosa; diuretics[ thiazide, Diamox);  in perhaps descending order of prevalence: fructose (now used as profuse sugar substitute in the cooldrink and fast food industry);  vitamin D3 deficiency; poorly controlled diabetes and insulin excess; alcoholism;  starvation and diarrhoea- malabsorption:- but especially chronic ingestion of phosphate-free antacids of sodium, calcium, magnesium and  especially  aluminium. Given the  accumulating toxicity of aluminium in bone and dementing diseases, there is no longer place for aluminium antacids, which should be banned.

A recent review of Medication-induced Hypophosphatemia from Greece stresses that diuretic and bisphosphonates (eg Elisaf ea 1998) are the chief causes. A 40year old article in the BMJ lists thiazides as a cause, although  Massry ea showed a decade later that thiazides blunt the hypercalciuria of phosphate depletion..
And this week a 3year study from Germany of 4000 women on oral bisphosphonate shows a median oral bisphosphonate treatment duration of 145.5 days. Persistence rates after 1 and 2 years were 27.9% and 12.9%, respectively. These abysmally poor medium-term compliance figures tell us how badly patients tolerate and view bisphosphonates.

Hence, dont use bisphosphonates for osteoporosis. There is no need for them  with their  major risks. Use appropriate harmless calcium-magnesium phosphate and vitamin D. There has never been convincing evidence to justify prescription of biSphosphonate for osteoporosis.

It is symptomatic of the pernicious influence of Big Pharma that the Wiki section on osteoporosis devotes dozens of lines to designer commercial drugs heavily promoted and prescribed by the Disease Industry, that have never been proven to be necessary let alone safe;  but only a few lines to the score of natural essentials that reverse both osteoporosis and all other common degenerative diseases of aging.     It doesnt even mention phosphate supplementation, though it mentions phosphate depletion as one of the many causative factors in osteoporosis- ignoring the fact that bisphosphonates actuallly worsen phosphate depletion in some studies. .

February 10, 2011    In today’s NEJM N Engl J Med  Bisphosphonates for Osteoporosis, Vis Dijkman and Lems at the hallowed VU Amsterdam bewail that a 67year old woman with osteoporosis was not treated with a bisphosphonate..

This is precisely the reflex response that marketeers of such synthetic drugs spend millions to obtain by doctored trials, massive advertising, ghosted papers in leading journals that crave such marketing adspend, and employment of spin doctors and lobbyists… to promote $billion sales.. . .

Although bisphosphonates and other modern designer drugs like strontium halve fracture rates, they cost a fortune, and have deadly albeit arguably rare risks; and have negligible need or indication except profiteering.

It is indeed medical malpractice when such patients are not placed on the economic safe multisystem protective supplements freely available in any democracy .

So where is the indication for such heavily advertized contentious patented designer drugs when they do nothing for multisystem health -especially frailty and falls, the chief risk factor for fractures – and all-cause morbidity and mortality?

When osteoporosis and all the other associated chronic major degenerative diseases of aging are at least halved, adding health to years, by the sensible combination of at least 20 micronutrients- fish oil, appropriate balanced human hormone replacement and a sensible powder blend of the vitamins, minerals and biologicals-that have each been shown to strengthen all-system health at little cost and no significant risk?

 update 29 Jan 2011 Prof Heaney's team showed in a 12 month trial published last year  that while  women on  a potent anabolic agent "with phosphate intake less than 1000mg/day,    phosphate and carbonate salts of calcium  appear to be approximately equally effective in supporting  vigorous bone building in osteoporosis ;   but  phosphate salt may be preferable in patients with restricted phosphorus intakes".  Combined Vitamin D and balanced sex hormones , the other minerals  and vitamins, are potent anabolic agents.

Hence it becomes clearer  from Heaney's and White's respective recent trials that since so many older women have relative calcium and phosphate deficiency- without obsessively checking  the plasma  calcium-phosphate product too regularly-  modest  supplementary tricalcium phosphate eg eg 1 gram a day can be given with eg modest calcium carbonate a gram a day to provide  about 700mg calcium and 200mg phosphate a day, safely  combined with the score of other natural bone-and muscle-anabolic supplements mentioned below and in previous reviews on this website. If the plasma  calcium and phosphate levels and product do not rise to the mid-upper range of healthy people despite all the other supplemments, if desireable  the dose of calcium phosphate can be titrated upwards and the calcium carb dose downwards .

It is intriguing that,  predictable hypocalcemic hyperphosphatemia from  chronic renal  failure  and hypoparathyroidism aside, on Pubmed and Google, phosphate overdose has  rarely been reported in adults , and then in bizarre circumstances.with gross overdose of eg sodium phosphate for purgation. Search for "calcium phosphate overdose" on Pubmed and Google reveals no case reports. Such is evidence-based medicine-  there is no report and thus no evidence of  serious  risk from appropriate use of oral calcium phosphate supplements.

By contrast, already by 1976 Heaney and Saville   showed that bisphosphonate elevated blood phosphate and calcium, but reduced both bone resorption and mineralization by about 50%.

Hence there is no place for bisphosphonates in the treatment of osteoporosis, when it is calcium-magnesium phosphate that is needed.

23 January 2011      Regulators, Administrators, medical schemes, Academics, specialists and family practitioners must produce evidence for patients to support why they (the Healthcare Industry)  promote patent synthetics like Fosamax - bisphosphonates BPN-  and  Pro(el)os  - strontium ranelate-  ahead of solidly evidence-based century-recognized and  balanced physiological safe low-cost natural multisupplements like vitamins, minerals and the past century,  appropriate human steroids. 

The accumulating evidence against synthetic designer drugs which target solely bone, and for well-proven combined safe approriate natural supplements  that benefit all bodily systems -has been updated regularly for bisphosphonates eg alendronate- the Fosamaxes - and strontium ranelate- Prot(e)os.  .  

In PHOSPHATE NUTRITION AND TREATMENT OF  OSTEOPOROSIS     Professor Robert Heaney in 2004   anaylses the crucial role of adequate phosphate in the elderly.     As we had hardwired into our brains in organic chemistry at med school 50 years ago, the main cation mineral elements in bone are calcium and phosphorus in the ratio of 2:1 in the matrix hydroxyapatite- [Ca3(PO4)2]3 Ca(OH)2; whereas potassium and magnesium are the main and thus most vital cellular ie intramuscular cations; and sodium (chloride) extracellularly. Thus while overall cationic mineral balance  including sodium is crucial,  calcium, magnesium, phosphorus and potassium are the main locomotion- strength -  cations. .   Heaney and Chris Nordin have for almost 50 years urged  dietary balance of calcium and phosphorus to optimize bone – why do doctors and Regulators continue to ignore this basic truth?

The association of calcium and phosphorus balance in senile osteoporosis goes back on Pubmed to at least 1953  if not to the 1930s.

But Pubmed and Wiki are  only  small windows on history.   It is salutory that on Pubmed  osteoporosis was already reported by Wherry  in a fulltext report dated 1894 ! It was already a scourge in Egyptian women 4000 years ago.    My thick  Lancet volume for 1839-40 does not list osteoporosis, nor does my  bulky 2 volume 1959 Oxford Universal Dictionary.

 Nor does my facimile  Sir William Osler’s Principles and Practice of Medicine 1892- but under rickets, for the frail child  it warmly recommends  milk as the chief food; phosphorus dissolved in olive oil; cod liver oil; and iron iodide given with the oil. And on the next page under scurvy, Osler discussed Dr James Lind’s  as yet unidentified antiscorbutic factor  which some felt might be due to the alkaline salts in fruit; with in children  fracturing scurvy very much like rickets  The Google layout of the 1901 edition  is of course longer, but the section on rickets treatment was identical.

 By WW2 Fuller Albright recognized one extra  major osteoporosis  link- menopause-  and began treating such women  successfully with estrogen replacement HRT.

So by WW2, decades before bisphosphonates for profit were thought of, mainstream medicine already knew about the chief nutrrients for healing bone-  cow’s milk for its calcium, potassium, protein and vitamin D; cod liver oil for its abundant vitamin D3;  iron, iodine, phosphates,  lemon juice for its vitamin C, and estrogen.

 Thus it is unsurprising that, apart from the major food components-  protein (nitrogen) and energy (starch and fats) ,   strength and upright posture and locomotion depends on maintenance of optimal micronutrients-  calcium magnesium potassium  phosphate, vitamins especially C and D,  and acid-base  balance  in the blood,  ie in the diet. 

It is common knowledge that as kidney function fails, with  unrestricted diet, acid and phosphate accumulate and calcium falls with calcification of vessels and tissues and weakening of  muscles and bones.       

But in average aging women (who mostly undergo loss of crucial anabolic steroid hormones in early  midlife,  decades younger than men), as Heaney says,  dietary phosphate deficiency becomes another major risk factor for osteoporosis- which is aggravated by  increasingly earlier menopause, vegetarianism, regression to tea and sandwiches diet, and increasing intolerance for dairy products and darker climate,  let alone  in devout muslim women applying cultural  avoidance of all sun exposure; and        

  •  the idiotic marketing and preaching of  pills like B-D-cal- which provide harmful unopposed daily 1500mg calcium as citrate or carbonate  with a trivial vitamin D3 dose of perhaps 400iu a day
  • aggravating the increasing calciferol deficiency from decreasing dairy intake; urban work indoors and no-longer compulsory sport at schools; and the idiotic omission of meaningful supplements of all the other essentials that become deficient with diet and aging- bone-and-muscle trophic minerals and vitamins especially magnesium, boron, selenium, manganese, zinc, iodine, even  strontium, fluoride;  and vitamins B, C, K;
  • and the modern irrational and adverse denial of appropriate  balanced physiological gonadal hormone replacement after age 60yrs.
  •   This is in turn worsened by the liberal use of purgatives;  calcium-magnesium-wasting furosemide,  SSRI antidepressants, corticosteroids and ethanol; and  aluminium and synthetic  antacids and deodorants rather than calcium magnesium salt.  

And as Heaney says, confusing  the phosphate retention of kidney failure with people with normal kidney function- who in fact have phosphorus depletion worsened by high calcium intake.    

       As he says,  supplement with  Calc (tri)phosphate works best, to provide  a positive phosphate balance of perhaps 90mg/day to maintain serum phosphate well within the healthy range of 1.5 to 2mmol/L. Calcium triphosphate provides some 400mg calcium and 200mg phosphorus per gram, thus 400mg a day of this salt will provide only 160mg calcium but perhaps adequate 80 mg phosphorus a day – dose to be adjusted simply on the blood calcium and phosphate levels if not just on progress in bone density restoration. The remaining adequate supplement of calcium- ~500mg/d -  is provided by eg calcium carbonate   1500mg a day, and of magnesium eg 300mg/day as mag -ox 500mg/day.     There is no reason why females should be far more vulnerable to fractures because of targeting merely the mediocre peak bone density of average women at 30yrs instead of that of young men.

 If everyone were encouraged to take safe vigorous combined appropriate supplements, premature aging diseases would fall greatly, cutting need for hospitalization, prescription modern drugs and acute-care specialists by far more than half ie putting thousand of health workers out of work other than to care for the increasing numbers of old survivors- pensioners. .

  So  it is now clear that Bisphosphonates and ranelate- Proteos/Protos- are unnecessary for osteoporosis when the latter is so easily healed and prevented by all the natural supplements discussed above, and when these patented synthetics designed solely for Big Pharma profit have rare but deadly adverse effects eg lethal DRESS syndrome, oesopageal ulceration-stenosis and cancer, and devastating teeth and jaw loss let alone collapse of the femur.

 NEW TRIAL SHOWS NATURAL PHOSPHATE IS BETTER THAN BISPHOSPHONATE :   Now a new paper from Liverpool University UK  by White ea confirms that natural phoshate supplement does better than bisphosphonate- alendronate, BNP- in restoring bone density  in patients..

This expose of the redundancy of potentially crippling BNPs comes just 10 years after Rogers et al in Scotland noted that “ After more than 30 years of clinical use, bisphosphonates’ molecular mechanisms of action are only just becoming clear”- they reduce bone resorption necessary for bone remodelling. .

But the BNP deception goes back a lot longer. Already in 1990 Prof  Reid ea in New Zealand showed that BNP produces a gradual rise in serum phosphate- BUT   ” an acute and sustained inhibition of bone resorption followed by a more gradual reduction in bone formation… over the 12 month period. “.  This explains clearly why BNPsreduce fracture rate in the shortterm, but can produce disasterous osteonecrosis and long bone fractures.

COMBINATION SUPPLEMENTS: In 1999 Reginster ea reported ia randomized controlled trial showing that lowdose monofluorophosphate MPF  (20mg fluoride) in osteoporotic women for 4 years decreased fracture rate as much as calcium supplement alone.   In 2009 Castel-Branco ea showed in a metaanalysis that hyroxyapatite was significanlty more protective than calcium alone.  

By 1999 the world’s   leading  osteoporosis research team – Christiansen and Riis, still active after 26 years together – showed  in a similar 2year trial that the  same dose MPF  plus 50ug estradiol and NETA produced an exciting 11.8% increase in spinal bonemass density compared to 4% on the HRT alone, and only 2.4% on the MPF alone. The same team in 1996 showed that in 15year followup, postmenopausal women fall into two groups: as opposed to the 70% majority slow bone losers, the 49 fast losers    “had at all sites significantly less bone mass than the normal bone losers (p < 0.001). 23 women had experienced a peripheral (Colles’) fracture and 25 a spinal fracture. The fracture groups had generally significantly (p < 0.05) less bone mass than the group without fracture, both in the forearm, spine, and hip and they also had the highest rate of bone loss after menopause (p < 0.05). Baseline bone mass and rate of loss predisposed to the same extent to fractures with ODD’s ratios of about 2. If both low bone mass and rate of loss were present, the ODD’s ratio increased to about 3.”    For three decades they have promoted appropriate estradiol and modern progestin replacement, withdrawal of which leads again to steady bone loss.

   So why are BNPs-  and increasingly strontium ranelate – - trumpeted as the most-prescribed drugs for osteoporosis? Quite simply- because health workers do what academics and professional bodies, Regulators and osteoporosis associations, politicians and Magnagement dictate- and thus what Big Pharma dictates since Big Pharma with its $multibillion  a year raincheck synthetic (but long term never  tested ) drugs pays such lobbyists well to research and register and promote their ever-new modern drugs before they go out of patent or are cancelled due to major adverse effects- or proof that they are actually useless. .

No matter how superior and safe combined supplements have been abundantly proven to be against fractures and all other common degenerative diseases of aging, no Big Pharma company is going to massmarket any supplements or combination of these when they are not patentable. So the  AntiOsteoporosis Big Pharma lobbyists- the FDA and academic researchers, are well rewarded to denigrate effective natural supplement combinations since these are not patentable. It  is obvious  that no  western ie allopathic Medical School  can resist ie function without the massive research funding from Big Pharma.

Balanced natural supplements (which we evolved on and from in available diet over aeons – which protect all systems in the body- reduce all diseases and mortality drastically. Their free availability as foodstuffs (and human HRT as prescription supplements)  is thus increasingly suppressed by eg the FDA, NHS , European Medicines Authority and medical schemes at the behest of their paymaster Big Pharma, for whom Only Disease Pays.

 Hence BNP  promotion and prescription for common osteoporosis is longstanding criminal fraud when simple supplements including phosphate heal bone without any of the horrendous   risks of BNPs. We dont need reminding that BNP  were developed to treat cancer bone pain ie terminal disease.  Their use for common osteoporosis has never been remotely justified.

One may thus well ask again- since natural phosphate and the other essential supplement micronutrients are abundant, low cost, and so safe (like everything else in life- in appropriate balanced dose)- and so well known to become deficient with ageing and restricted diet- why did and do Authorities and Regulators allow heavily marketed synthetics phosphate salts- BNPs – and synthetic strontium salt- to be launched and continued to saturate the market before there was good proof of both need for them and evidence of long term safety, lack of major adverse effects?

It is trite to repeat that Regulators are there to protect the public- in this case consumers, patients- not promote reckless profiteering by ruthless corporates.

The essential role of abundant phosphate in diet was already exquisitely described by Harmon ea from Illinois in 1974 in pigs, (whose physiology so closely resembles humans)  where paralysis and bone loss were prevented simply by adequate phosphate diet supplement to improve the calcium:phosphate balance in diet from about 2:1 to 1.4:1. The paper details references going back decades- so the benefits of adequate phosphates were already long and well known to science.

 In the face of such simple nutritional benefit of natural microsupplements, why else except for commercial gain would research on BNPs already be reported since 1958?  and their use against osteoporosis since 1971?   Guanabens already reported BNP -associated long bone fracture in 1994 ; and he reviews the problem of vitamin D and phosphate deficiency related osteomalacia in a study a few months ago. 

It is painfully obvious that synthetic drugs like BNPs  that produce low bone turnover will cause brittle bones- osteomalacia, as Whyte reviewed in 2009.  So why use such drugs, when all that patients need – if they cant take abundant sunshine and milk- is some balanced lowcost multisupplements.   So it becomes increasingly negligent to promote, prescribe the synthetic drugs BNPs and SrRanelate, and high calcium-low vitamin D pills; and withhold balanced proven multisupplements.

Why do Regulators and so-called Expert Committees allow BNPs, SrRan  and high calcium-low vitamin D pills (followed by expensive patents like synthetic designer  HRT – xenohormones, and calcitonin and terapeptide ), to be the “most popular prescriptions” for osteoporosis (dictated largely by Big Pharma, and surgeons- gynecologists and orthopaedists – not metabolic nutrition-physiology-based endocrinologists and dieticians) – unless such authorities are in commercial cartel collusion with Big Pharma and the  fracture industries against patients’ interests? Why are payors and the most vulnerable older women- patients and others- allowed to be fleeced, preyed on  like this for profiteering by poor health?